Evoke Pharma, Inc

(NASDAQ:EVOK)

Latest On Evoke Pharma, Inc (EVOK):

Date/Time Type Description Signal Details
2023-05-15 23:33 ESTNewsEvoke Pharma GAAP EPS of -$0.67 misses by $0.09, revenue of $0.81M misses by $0.19MN/A
2023-03-21 19:42 ESTNewsEvoke Pharma GAAP EPS of $0.54 beats by $1.07, revenue of $0.79M misses by $0.1MN/A
2023-03-21 19:42 ESTNewsEvoke Pharma, Inc. (EVOK) Q4 2022 Earnings Call TranscriptN/A
2023-03-21 04:27 ESTNewsEvoke Pharma Q4 2022 Earnings PreviewN/A
2023-01-30 13:54 ESTNewsEvoke stock rises on filing of dismissal in nasal spray Gimoti's patent infringement caseN/A
2022-12-07 12:02 ESTNewsEvoke Pharma receives patent for Gimoti to treat moderate to severe gastroparesisN/A
2022-11-30 17:08 ESTNewsEvoke Pharma to get US patent linked to nasal spray GimotiN/A
2022-11-09 23:48 ESTNewsEvoke Pharma GAAP EPS of -$0.60 beats by $0.06, revenue of $0.83M beats by $0.26MN/A
2022-11-09 23:48 ESTNewsEvoke Pharma, Inc. (EVOK) Q3 2022 Results - Earnings Call TranscriptN/A
2022-11-09 05:30 ESTNewsEvoke Pharma Q3 2022 Earnings PreviewN/A
2022-09-20 15:59 ESTNewsEvoke to get US patent for nasal spray GimotiN/A
2022-08-17 00:40 ESTNewsEvoke, Eversana to launch telehealth solution for GimotiN/A
2022-08-11 09:11 ESTNewsEvoke Pharma Q2 GAAP loss per share narrows, revenue upN/A
2022-08-11 09:11 ESTNewsEvoke Pharma, Inc. (EVOK) CEO David Gonyer on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-09 23:57 ESTNewsEvoke Pharma Q2 2022 Earnings PreviewN/A
2022-07-06 22:03 ESTNewsEvoke Pharma gets Canadian patent linked to Gimoti nasal sprayN/A
2022-06-16 01:42 ESTNewsEvoke jumps on approval for nasal spray Gimoti being added to Florida's Medicaid programN/A
2022-06-08 18:48 ESTNewsEvoke Pharma regains compliance with Nasdaq listing requirementsN/A
2022-05-23 18:53 ESTNewsEvoke stock down 24% as study shows lower risk of tardive dyskinesia among patients treated with metoclopramideN/A
2022-05-11 03:20 ESTNewsEvoke Pharma GAAP EPS of -$0.07 misses by $0.03, revenue of $0.42M misses by $0.12MN/A
2022-05-11 03:19 ESTNewsEvoke Pharma, Inc. (EVOK) CEO David Gonyer on Q1 2022 Results - Earnings Call TranscriptN/A
2022-03-09 06:28 ESTNewsEvoke Pharma GAAP EPS of $0.05 beats by $0.13, revenue of $0.36M misses by $0.15MN/A
2022-03-09 06:28 ESTNewsEvoke Pharma, Inc. (EVOK) CEO Dave Gonyer on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-07 19:24 ESTNewsEvoke Pharma Q4 2021 Earnings PreviewN/A
2022-02-02 18:23 ESTNewsEvoke Pharma, Eversana extend commercialization contract for GimotiN/A
2021-11-11 05:32 ESTNewsEvoke Pharma's (EVOK) CEO Dave Gonyer on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-10 07:28 ESTNewsEvoke Pharma Q3 2021 Earnings PreviewN/A
2021-10-21 05:03 ESTNewsEvoke Pharma highlights positive findings from Gimoti market research studyN/A
2021-08-13 13:02 ESTNewsEvoke Pharma, Inc. (EVOK) CEO David Gonyer on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-12 16:41 ESTNewsEvoke Pharma EPS beats by $0.01, beats on revenueN/A
2021-07-21 07:58 ESTNewsEvoke Pharma issued new U.S. patent covering methods of use for GimotiN/A
2021-07-21 07:52 ESTNewsEvoke Pharma pops 8% after Gimoti listed in FDA Orange BookN/A
2021-07-21 07:45 ESTNewsEvoke Pharma announces positive findings from second GIMOTI market research studyN/A
2021-07-21 07:15 ESTNewsEvoke Pharma launches GIMOTI patient and physician experience programN/A
2021-04-06 20:28 ESTNewsEvoke Pharma gets notice of allowance from United States Patent and Trademark OfficeN/A
2021-03-12 07:38 ESTFinancialsCompany financials have been released.Neutral
2021-03-12 07:38 ESTEarnings EstimateAn EPS average of $0.39 is estimated for the 2022 year.Buy
2021-03-12 07:38 ESTEarnings EstimateAn EPS average of -$0.04 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-12 03:22 ESTNewsEvoke Pharma EPS beats by $0.05N/A
2021-03-12 03:22 ESTNewsEvoke Pharma, Inc. (EVOK) CEO Dave Gonyer on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-12 03:22 ESTNewsEvoke Pharma (EVOK) net loss widened in Q4, shares plunge 29%N/A
2021-02-10 11:00 ESTNewsEvoke Pharma: Opportunity For Upside As Gimoti Sales RampN/A
2021-01-14 19:06 ESTNewsEvoke Pharma slips 7% after pricing equity offeringN/A
2021-01-14 03:42 ESTNewsEvoke Pharma under pressure on proposed public offeringN/A
2021-01-13 13:14 ESTNewsEvoke Pharma shares surge on positive findings from Gimoti market research studyN/A
2020-11-26 19:56 ESTFinancialsCompany financials have been released.Neutral
2020-11-12 03:52 ESTFinancialsCompany financials have been released.Neutral
2020-11-11 11:46 ESTEarnings EstimateAn EPS average of -$0.06 is estimated for the quarter ending on March 31, 2021.Buy
2020-11-10 13:02 ESTNewsEvoke Pharma EPS beats by $0.02N/A
2020-11-07 15:46 ESTFinancialsCompany financials have been released.Neutral

About Evoke Pharma, Inc (EVOK):

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase III clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

EVOK Quotes by TradingView

See Advanced Chart

General

  • Name Evoke Pharma, Inc
  • Symbol EVOK
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryDrug Manufacturers-Specialty & Generic
  • Full Time Employees 5
  • Fiscal Year EndDecember
  • IPO Date2013-09-25
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://www.evokepharma.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 2635.59
  • Price/Book (Most Recent Quarter) 19.62
  • Enterprise Value Revenue 3224.25
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.20
  • Next Year EPS Estimate -$0.18
  • Operating Margin -56678%
  • Return on Assets -103%
  • Return on Equity -2257%
  • Revenue 23020
  • Earnings Per Share -$0.40
  • Revenue Per Share $0
  • Gross Profit -63692
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 75.75 million
  • PEG Ratio -0.1
  • Analyst Target Price $9.5
  • Book Value Per Share $0.12
View More

Share Statistics

  • Shares Outstanding 32.37 million
  • Shares Float 27.55 million
  • % Held by Insiders 392%
  • % Held by Institutions 14.97%
  • Shares Short 731718
  • Shares Short Prior Month 493780
  • Short Ratio 0.74
  • Short % of Float 2%
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta 1.43
  • 52 Week High $6.06
  • 52 Week Low $0.82
  • 50 Day Moving Average 3.02
  • 200 Day Moving Average 3.55
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Evoke Pharma, Inc (EVOK) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Evoke Pharma, Inc (EVOK) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-11$23020-$0.09-$0.1433.33%
2020-09-302020-11-10$N/A-$0.08-$0.1020%
2020-06-302020-08-06$N/A-$0.28-$0.08-250%
2020-03-312020-05-12$N/A-$0.07-$0.05-40%
2019-12-312020-03-12$N/A-$0.06-$0.060%
2019-09-302019-11-07$N/A-$0.07-$0.0922.22%
2019-06-302019-08-08$N/A-$0.09-$0.1225%
2019-03-312019-05-08$N/A-$0.11-$0.07-57.14%
2018-12-312019-03-06$N/A-$0.10-$0.07-49.93%
2018-09-302018-11-13$N/A-$0.09-$0.08-12.5%
2018-06-302018-08-09$N/A-$0.14-$0.1613.58%
2018-03-312018-05-14$N/A-$0.13-$0.1929.73%
2017-12-312018-03-07$N/A-$0.02-$0.2391.38%
2017-09-302017-11-14$N/A-$0.34-$0.20-68.32%
2017-06-302017-08-14$N/A-$0.11-$0.1735.29%
2017-03-312017-05-15$N/A-$0.37-$0.16-127.69%
2016-12-312017-03-15$N/A-$0.12-$0.1938.14%
2016-09-302016-11-09$N/A-$0.29-$0.25-14.17%
2016-06-302016-08-15$N/A-$0.41-$0.433.82%
2016-03-312016-05-11$N/A-$0.45-$0.41-9.22%
2015-12-312016-03-10$N/A-$0.37-$0.4518.56%
2015-09-302015-11-12$N/A-$0.42-$0.5422.22%
2015-06-302015-08-13$N/A-$0.52-$0.6013.33%
2015-03-312015-05-14$N/A-$0.58-$0.55-5.45%
2014-12-312015-03-04$N/A-$0.48-$0.6829.41%
2014-09-302014-11-13$N/A-$0.63-$0.7819.23%
2014-06-302014-08-13$N/A-$0.59-$0.6610.61%
2014-03-312014-05-13$N/A-$0.49-$0.36-36.11%
2013-12-312014-03-25$N/A-$0.21-$0.16-31.25%
2013-09-302013-11-13$N/A-$0.38-$0.10-280%

Evoke Pharma, Inc (EVOK) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Evoke Pharma, Inc (EVOK) Chart:

Evoke Pharma, Inc (EVOK) News:

Below you will find a list of latest news for Evoke Pharma, Inc (EVOK) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Evoke Pharma, Inc (EVOK) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest EVOK Trades:

Date Shares Price
Jun 13, 2022 2:26 PM EST5$2.235

Evoke Pharma, Inc (EVOK) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459020029929/0001564590-20-029929-index.htm
2017-11-28UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1403708/000000000017041649/0000000000-17-041649-index.htm
2018-05-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1403708/000117891318001517/0001178913-18-001517-index.htm
2020-02-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1403708/000117891320000337/0001178913-20-000337-index.htm
2017-11-14S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1403708/000119312517342602/0001193125-17-342602-index.htm
2017-12-12S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1403708/000119312517367595/0001193125-17-367595-index.htm
2017-12-12CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1403708/000119312517367598/0001193125-17-367598-index.htm
2017-12-26CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1403708/000119312517378710/0001193125-17-378710-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000119312519003246/0001193125-19-003246-index.htm
2018-04-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919118026542/0001209191-18-026542-index.htm
2018-04-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919118026548/0001209191-18-026548-index.htm
2018-04-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919118026555/0001209191-18-026555-index.htm
2018-04-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919118026566/0001209191-18-026566-index.htm
2018-04-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919118026570/0001209191-18-026570-index.htm
2018-04-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919118026574/0001209191-18-026574-index.htm
2018-04-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919118026577/0001209191-18-026577-index.htm
2018-04-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919118026582/0001209191-18-026582-index.htm
2018-04-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919118026595/0001209191-18-026595-index.htm
2018-08-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919118047750/0001209191-18-047750-index.htm
2018-09-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919118049419/0001209191-18-049419-index.htm
2018-09-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919118049420/0001209191-18-049420-index.htm
2018-09-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919118049421/0001209191-18-049421-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919119008467/0001209191-19-008467-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919119008473/0001209191-19-008473-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919119008477/0001209191-19-008477-index.htm
2019-05-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919119027498/0001209191-19-027498-index.htm
2019-05-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919119027500/0001209191-19-027500-index.htm
2019-05-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919119027513/0001209191-19-027513-index.htm
2019-05-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919119027530/0001209191-19-027530-index.htm
2019-05-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919119027534/0001209191-19-027534-index.htm
2019-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919119038030/0001209191-19-038030-index.htm
2019-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919119038034/0001209191-19-038034-index.htm
2019-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919119038036/0001209191-19-038036-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919120015796/0001209191-20-015796-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919120015803/0001209191-20-015803-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919120015842/0001209191-20-015842-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919120032964/0001209191-20-032964-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919120032965/0001209191-20-032965-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919120032971/0001209191-20-032971-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919120032973/0001209191-20-032973-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919120032986/0001209191-20-032986-index.htm
2020-09-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919120049014/0001209191-20-049014-index.htm
2020-09-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919120049015/0001209191-20-049015-index.htm
2020-09-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1403708/000120919120049016/0001209191-20-049016-index.htm
2017-10-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459017019709/0001564590-17-019709-index.htm
2017-11-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459017023007/0001564590-17-023007-index.htm
2017-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1403708/000156459017023771/0001564590-17-023771-index.htm
2017-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459017023783/0001564590-17-023783-index.htm
2018-02-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459018002154/0001564590-18-002154-index.htm
2018-03-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459018004312/0001564590-18-004312-index.htm
2018-03-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459018004724/0001564590-18-004724-index.htm
2018-03-0710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1403708/000156459018004725/0001564590-18-004725-index.htm
2018-03-16DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1403708/000156459018005959/0001564590-18-005959-index.htm
2018-03-16DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1403708/000156459018005960/0001564590-18-005960-index.htm
2018-03-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459018006616/0001564590-18-006616-index.htm
2018-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459018006712/0001564590-18-006712-index.htm
2018-04-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459018007604/0001564590-18-007604-index.htm
2018-04-068-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459018007773/0001564590-18-007773-index.htm
2018-04-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459018009455/0001564590-18-009455-index.htm
2018-04-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459018009679/0001564590-18-009679-index.htm
2018-05-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459018012710/0001564590-18-012710-index.htm
2018-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459018013307/0001564590-18-013307-index.htm
2018-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1403708/000156459018013308/0001564590-18-013308-index.htm
2018-05-14S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1403708/000156459018013309/0001564590-18-013309-index.htm
2018-06-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459018014972/0001564590-18-014972-index.htm
2018-08-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459018021032/0001564590-18-021032-index.htm
2018-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1403708/000156459018021043/0001564590-18-021043-index.htm
2018-08-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459018021862/0001564590-18-021862-index.htm
2018-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459018029307/0001564590-18-029307-index.htm
2018-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1403708/000156459018029310/0001564590-18-029310-index.htm
2019-03-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459019005936/0001564590-19-005936-index.htm
2019-03-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459019006402/0001564590-19-006402-index.htm
2019-03-0610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1403708/000156459019006404/0001564590-19-006404-index.htm
2019-03-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459019007668/0001564590-19-007668-index.htm
2019-03-21DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1403708/000156459019008728/0001564590-19-008728-index.htm
2019-03-21DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1403708/000156459019008729/0001564590-19-008729-index.htm
2019-04-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459019010479/0001564590-19-010479-index.htm
2019-05-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459019015728/0001564590-19-015728-index.htm
2019-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459019017197/0001564590-19-017197-index.htm
2019-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1403708/000156459019017213/0001564590-19-017213-index.htm
2019-05-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459019019744/0001564590-19-019744-index.htm
2019-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459019022866/0001564590-19-022866-index.htm
2019-06-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459019023669/0001564590-19-023669-index.htm
2019-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459019030431/0001564590-19-030431-index.htm
2019-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1403708/000156459019030433/0001564590-19-030433-index.htm
2019-09-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459019034828/0001564590-19-034828-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459019041383/0001564590-19-041383-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1403708/000156459019041384/0001564590-19-041384-index.htm
2019-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459019043107/0001564590-19-043107-index.htm
2019-12-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459019044974/0001564590-19-044974-index.htm
2019-12-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459019046456/0001564590-19-046456-index.htm
2020-01-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459020001397/0001564590-20-001397-index.htm
2020-01-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459020001783/0001564590-20-001783-index.htm
2020-01-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459020001964/0001564590-20-001964-index.htm
2020-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459020010253/0001564590-20-010253-index.htm
2020-03-1210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1403708/000156459020010254/0001564590-20-010254-index.htm
2020-04-14DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1403708/000156459020016563/0001564590-20-016563-index.htm
2020-04-14DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1403708/000156459020016566/0001564590-20-016566-index.htm
2020-05-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1403708/000156459020024523/0001564590-20-024523-index.htm
2020-05-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459020024527/0001564590-20-024527-index.htm
2020-05-12DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1403708/000156459020024528/0001564590-20-024528-index.htm
2020-05-13DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1403708/000156459020024766/0001564590-20-024766-index.htm
2020-05-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459020026257/0001564590-20-026257-index.htm
2020-05-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459020027126/0001564590-20-027126-index.htm
2020-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459020029929/0001564590-20-029929-index.htm
2020-07-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459020031991/0001564590-20-031991-index.htm
2020-07-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459020032391/0001564590-20-032391-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459020037293/0001564590-20-037293-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1403708/000156459020037301/0001564590-20-037301-index.htm
2020-08-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459020041182/0001564590-20-041182-index.htm
2020-09-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459020042364/0001564590-20-042364-index.htm
2020-10-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1403708/000156459020047511/0001564590-20-047511-index.htm
2018-01-16SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1403708/000168316818000125/0001683168-18-000125-index.htm
2019-01-17SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1403708/000168316819000154/0001683168-19-000154-index.htm
2017-12-28EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1403708/999999999517003343/9999999995-17-003343-index.htm
2018-04-18CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1403708/999999999718004977/9999999997-18-004977-index.htm
2018-06-20CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1403708/999999999718006499/9999999997-18-006499-index.htm
2019-06-24SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1403708/999999999719005745/9999999997-19-005745-index.htm
2019-06-04SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1403708/999999999720001384/9999999997-20-001384-index.htm

Evoke Pharma, Inc (EVOK) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Evoke Pharma, Inc (EVOK). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 392%
Institutional Ownership: 1497%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-08-20LVP GP III, LLC10% Share HolderBuy465,116.002.351,093,022.601,937,983.00https://www.sec.gov/Archives/edgar/data/1403708/000120919118047750/0001209191-18-047750-index.htm
2020-03-02Matthew J D'OnofrioExec VP, Chief Bus. OfficerBuy25,000.000.8521,250.00263,759.00https://www.sec.gov/Archives/edgar/data/1403708/000120919120015803/0001209191-20-015803-index.htm
2018-08-20LVP GP III, LLC10% Share HolderBuy11,628.002.3527,325.8048,449.00https://www.sec.gov/Archives/edgar/data/1403708/000120919118047750/0001209191-18-047750-index.htm
2018-08-20LVP GP III, LLC10% Share HolderBuy23,256.002.3554,651.6096,897.00https://www.sec.gov/Archives/edgar/data/1403708/000120919118047750/0001209191-18-047750-index.htm